Oncotelic Therapeutics to Present Novel Breast Cancer Treatment Data at 2025 Symposium
Oncotelic Therapeutics will present clinical data for its investigational breast cancer treatment Sapu003 at the 2025 San Antonio Breast Cancer Symposium, potentially offering improved efficacy and reduced toxicity for patients with HR⁺/HER2⁻ metastatic breast cancer.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that clinical data for Sapu003, an investigational intravenous Deciparticle™ formulation of everolimus, has been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium scheduled for December 9-12, 2025, in San Antonio, Texas. The presentation represents a significant milestone for the biopharmaceutical company and its joint venture partner Dragon Oversea in developing Sapu003 through their Sapu Nano collaboration.
The importance of this development lies in Sapu003's potential to address critical limitations of current breast cancer treatments. The novel Deciparticle™ formulation is specifically designed to improve bioavailability, reduce toxicity, and enhance tumor penetration in HR⁺/HER2⁻ metastatic breast cancer, renal cell carcinoma (RCC), and neuroendocrine tumors (NET). For breast cancer patients, this could translate to more effective treatment with fewer side effects, potentially improving quality of life during therapy.
Oncotelic Therapeutics operates as a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products, with a mission to address high-unmet-need cancers and rare pediatric indications. The company benefits from the extensive intellectual property portfolio of CEO Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. This foundation of innovation supports the development of transformative cancer therapies through Oncotelic's PDAOAI platform and expertise in nanomedicines.
The company's strategic approach extends beyond internal development programs through joint venture partnerships. Oncotelic currently owns 45% of GMP Bio, another joint venture under Dr. Trieu's leadership that is advancing its own pipeline of drug candidates. This diversified development strategy strengthens Oncotelic's position in oncology and rare disease therapeutics while spreading risk across multiple promising candidates. Investors can access the latest news and updates relating to OTLC through the company's newsroom at https://ibn.fm/OTLC.
The acceptance of Sapu003 data for presentation at one of the world's premier breast cancer conferences signals growing scientific interest in the Deciparticle™ technology platform. The San Antonio Breast Cancer Symposium attracts leading oncology researchers and clinicians worldwide, providing an important venue for showcasing innovative approaches to cancer treatment. For patients with HR⁺/HER2⁻ metastatic breast cancer who often face limited treatment options as their disease progresses, new therapeutic approaches like Sapu003 could represent meaningful advances in care.
As the biopharmaceutical industry continues to seek more targeted and less toxic cancer treatments, nanomedicine approaches such as the Deciparticle™ technology platform offer potential solutions to longstanding challenges in drug delivery and efficacy. The upcoming presentation will provide the oncology community with crucial data on whether Sapu003 can deliver on its promise of improved bioavailability and reduced toxicity while maintaining or enhancing anti-tumor activity in difficult-to-treat cancers.